Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.

New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.

Trulicity’s broad CV label awarded by the US FDA should aid overall uptake of the GLP-1 class, cushioning the direct impact on Novo Nordisk’s rival, Ozempic, analysts said.

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…

GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.